Who is sponsoring NCT07183020?

NCT07183020 is sponsored by Skripuletz, Thomas Prof. Dr..

What drugs are being tested in NCT07183020?

Interventions in NCT07183020: Oligoclonal bands and kappa free light chains (KFLC).

What condition does NCT07183020 study?

NCT07183020 studies Multiple Sclerosis, Clinically Isolated Syndrome (CIS).

Is NCT07183020 still recruiting?

NCT07183020 is currently enrolling by invitation. Last updated 19 September 2025.

Last reviewed 2025-09-19 · How we verify

NCT07183020: PRO-KFLC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Kappa Free Light Chains (KFLC) in Multiple Sclerosis (MS) and Clinically Isolated Syndrome (CIS)

ENROLLING BY INVITATION Last updated 19 September 2025

What this trial tests

trial testing Oligoclonal bands and kappa free light chains (KFLC) in Multiple Sclerosis in 1,142 participants. Enrolling by invitation.

Timeline

27 October 2022

Primary endpoint
31 July 2026

31 December 2026

Quick facts

Lead sponsor	Skripuletz, Thomas Prof. Dr.
Status	ENROLLING BY INVITATION
Study type	OBSERVATIONAL
Enrollment	1,142
Start date	27 October 2022
Primary completion	31 July 2026
Estimated completion	31 December 2026
Sites	1 location across Germany

Drugs / interventions tested

Oligoclonal bands and kappa free light chains (KFLC)

Conditions studied

Multiple Sclerosis — all drugs for Multiple Sclerosis →
Clinically Isolated Syndrome (CIS) — all drugs for Clinically Isolated Syndrome (CIS) →

Sponsor

Skripuletz, Thomas Prof. Dr.

Who can join

Adults 18 to 70, any sex, with Multiple Sclerosis or Clinically Isolated Syndrome (CIS). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to learn about the role of kappa free light chains (KFLC) in cerebrospinal fluid (CSF) in the diagnosis of multiple sclerosis (MS) and clinically isolated syndrome (CIS). The main question it aims to answer is: Are KFLC superior, inferior or equally useful in the diagnostic work-up of CSF of patients with MS and CIS? In CSF and serum sample pairs of patients diagnosed with MS or CIS, KFLC are measured using a nephelometric assay and are compared with the gold standard, of CSF diagnostics, oligoclonal bands.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

NCT07507084 — The Effect of Internal- or External-Focused Exercise Training, Administered in Conjunction With a Cognitive Task, on Wal · NA · recruiting
NCT07524231 — Evaluation of the Effects of Laughter Yoga · NA · recruiting
NCT07489794 — URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSIS · recruiting
NCT07236684 — Identification of Factors Related to UI in Patients With MS and EMG Assessment of PFM Activity · recruiting
NCT07500727 — Skeletal Muscle Aging and Responsiveness in Aged People With MS · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07183020 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Skripuletz, Thomas Prof. Dr.
Last refreshed: 19 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07183020.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing